Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 81.70

-0.1%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (2600)	6/20/1999 8:39:00 PM
From: Scott H. Davis	of 4676

Mike, IMSCO, ISIP will be a lot less niche after they improve their technology sufficiently to provide sufficient bio-availability via systemic administration. The CMV ret med was 1st generation antisense direct injected into an area with reduced outside blood flow. Another test program was scrapped when early results with a 2nd (or was that 3rd) generation version attaching the same indication yielded sufficiently better results that the partner wanted to go full ahead with the 2nd generation. I don't have the credentials you look for, but as a clinical analyst working with Rx and lab for years, I do understand enough pharmacokinetics to see the applicability to larger indications once the tech has progressed sufficiently. Scott And RE VICL, I'd suggest getting their annual report. Good, suscinct info, can be requested free online via the NASDAQ site (and still my favorite biotech balancing long term potertial vs risk)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next